{"doi":"10.1016/j.jcjo.2021.10.008","title":"Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis","abstract":null,"journal":"Canadian Journal of Ophthalmology","year":2023,"id":645353,"datarank":0.4887144807032224,"base_score":3.258096538021482,"endowment":3.258096538021482,"self_citation_contribution":0.4887144807032224,"citation_network_contribution":0.0,"self_endowment_contribution":0.4887144807032224,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":25,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1680369,"name":"Justin S. Yu","orcid":null,"position":1,"is_corresponding":false},{"id":1680370,"name":"Alexandros Sagkriotis","orcid":null,"position":2,"is_corresponding":false},{"id":1680371,"name":"Guruprasad B","orcid":"0000-0001-5383-2634","position":3,"is_corresponding":false},{"id":1680372,"name":"Bhavya Burugapalli","orcid":null,"position":4,"is_corresponding":false},{"id":1680373,"name":"Xiaoyu Bi","orcid":null,"position":5,"is_corresponding":false},{"id":1680374,"name":"Neetu Agashivala","orcid":null,"position":6,"is_corresponding":false},{"id":325315,"name":"Charles C. Wykoff","orcid":"0000-0001-7756-5091","position":7,"is_corresponding":false},{"id":407553,"name":"Mathew W. MacCumber","orcid":"0000-0003-1063-1124","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis","abstract":"<h4>Objective</h4>To evaluate treatment patterns and outcomes of patients in the United States who received antivascular endothelial growth factor (anti-VEGF) agents for wet age-related macular degeneration (AMD).<h4>Design</h4>Retrospective study PARTICIPANTS: Patients with wet AMD.<h4>Methods</h4>Using the Intelligent Research in Sight Registry, we studied patients with wet AMD who received ≥1 anti-VEGF injection, who were ≥50 years old, and with ≥1.5 years of follow-up. Patients were grouped based on follow-up duration (in years): ≥1.5 (cohort 1), ≥2.5 (cohort 2), and ≥3.5 (cohort 3).<h4>Results</h4>Patient characteristics were similar between treatment groups. 36.8%, 34.5%, and 39.2% of ranibizumab, aflibercept, and all anti-VEGF eyes, respectively, had an injection interval <8 weeks in length at the end of year 1. Results were similar at year 2 and 3. In cohorts 1-3, visual acuity (VA) changes from baseline ranged from 0.3 to 0.7 (year 1), -1.3 to -1.7 (year 2), and -2.8 to -3.1 (year 3) Early Treatment Diabetic Retinopathy Study letters. By the end of year 3, 41%, 39%, and 42% of ranibizumab, aflibercept, and all anti-VEGF eyes, respectively, had discontinued treatment (no injection for >6 months).<h4>Conclusion</h4>Approximately one-third of eyes had injection intervals <8 weeks in length at the end of year 1. VA was slightly better at the end of year 1 and declined after the first year despite treatment. By the end of year 3, more than one-third of eyes had discontinued treatment. Given the high treatment burden, wet AMD patients may benefit from more durable approaches that require less frequent dosing.","is_dataset_classified":null,"base_score":3.258096538021482,"endowment":3.258096538021482,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"34863677","pmcid":null,"openalex_id":"https://openalex.org/W4200460276","authors":[],"funders":[{"funder_name":"Novartis","grant_id":"","title":null},{"funder_name":"Novartis Pharmaceuticals Corporation","grant_id":"","title":null}],"total_grants":2,"fwci":3.5945,"citation_percentile":0.93940678,"influential_citations":2,"citation_trend":[{"year":2022,"count":2},{"year":2023,"count":13},{"year":2024,"count":5},{"year":2025,"count":3},{"year":2026,"count":2}],"oa_status":"closed","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0008418221003951?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0008418221003951?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.jcjo.2021.10.008","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/34863677","host_type":"repository"}],"fields_of_study":["Retinal Diseases and Treatments","Ophthalmology and Visual Impairment Studies","Retinopathy of Prematurity Studies","Medicine"],"mesh_terms":["Ranibizumab","Humans","Middle Aged","Recombinant Fusion Proteins","Registries","Retrospective Studies","Endothelial Growth Factors","Angiogenesis Inhibitors","Receptors, Vascular Endothelial Growth Factor","Vascular Endothelial Growth Factor A","Wet Macular Degeneration","Intravitreal Injections"],"keywords":["Ranibizumab","Aflibercept","Medicine","Macular degeneration","Cohort","Ophthalmology","Visual acuity","Retrospective cohort study","Diabetic retinopathy","Choroidal neovascularization","Bevacizumab","Surgery","Internal medicine","Diabetes mellitus","Chemotherapy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-09T05:02:06.263470Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}